Farletuzumab ecteribulin and MORAb‐109, folate receptor alpha and mesothelin targeting antibody–drug conjugates, show activity in poor prognosis gynaecological cancer models by Ksenija Nesic, Katherine Rybinski, Gayanie Ratnayake, Gwo‐Yaw Ho, Ratana Lim, Marc Radke, Chloe Neagle, Elizabeth M. Swisher, Matthew J. Wakefield, Holly E. Barker, Keiji Furuuchi, Clare L. Scott, Cassandra J. Vandenberg

Get full text